Insulin Dose Calculation Software in Insulin Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insulin therapy is the mainstream glucose-lowering program for hospital glucose management. Intelligent insulin dose calculation software based on fingertip glucose monitoring is born in response to the situation. A new generation of continuous blood glucose monitoring technology compared with traditional monitoring technology provides more abundant blood sugar change information.The development of the continuous glucose monitoring technology espcially in blood sugar change trend arrow information, the intelligent insulin dose adjustment sequence based on WeChat program is developed. We plan to carry out a randomized controlled study on patients receiving insulin therapy, in which the insulin dose is adjusted according to the information of four blood glucose monitoring points (before meals and before bed), and randomly divided into two groups, one group is adjusted according to the experience of clinicians, the other group is adjusted according to Wechat program, and glucose monitoring is continued for 1 week. bBood glucose control index of TIR , and the incidence of hypoglycemia and hyperglycemia, hospitalization days and cost was observed. This study ihas great clinical value.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards

NCT06319300

Diabetes Type 2

RECRUITING NA

Artificial Intelligence Assisted Insulin Titration System

NCT04053959

Type 2 Diabetes

COMPLETED PHASE4

Insulin Titration System Based on Deep Learning

NCT05409391

Diabetes Mellitus Type 2 - Insulin-Treated

COMPLETED NA

Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients

NCT04642378

Type 2 Diabetes

COMPLETED NA

Evaluation of Efficacy and Safety of Insulin Glargine Injected by Needle-free Jet Syringe

NCT04093284

Diabetes Mellitus, Type 2

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The problems related to blood glucose in non-endocrine departments are becoming more and more serious.Glucose control level is closely related to the prognosis and cost of inpatients. Insulin therapy is the mainstream glucose-lowering program for hospital glucose management. Intelligent insulin dose calculation software based on fingertip glucose monitoring is born in response to the situation. A new generation of continuous blood glucose monitoring technology compared with traditional monitoring technology provides more abundant blood sugar change information.The development of the continuous glucose monitoring technology espcially in blood sugar change trend arrow information, the intelligent insulin dose adjustment sequence based on WeChat program is developed. We plan to carry out a randomized controlled study on patients receiving insulin therapy, in which the insulin dose is adjusted according to the information of four blood glucose monitoring points (before meals and before bed), and randomly divided into two groups, one group is adjusted according to the experience of clinicians, the other group is adjusted according to Wechat program, and glucose monitoring is continued for 1 week. bBood glucose control index of TIR , and the incidence of hypoglycemia and hyperglycemia, hospitalization days and cost was observed. This study ihas great clinical value.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Time in Range Artificial Intelligence Insulin Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wechat program guidance group

Wechat program guidance group using insulin dose calculator

Group Type EXPERIMENTAL

Wechat program

Intervention Type DEVICE

The experimental group used wechat program to calculate insulin dose to guide insulin treatment .

clinical experience treatment group

clinical experience treatment group using physician experience

Group Type ACTIVE_COMPARATOR

Wechat program

Intervention Type DEVICE

The experimental group used wechat program to calculate insulin dose to guide insulin treatment .

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wechat program

The experimental group used wechat program to calculate insulin dose to guide insulin treatment .

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Non-endocrine departments;
* 2\. Age 18-70;
* 3\. Currently using intensive insulin therapy with basic meals;
* 4\. Belong to type 1 or Type 2 diabetes
* 5\. Hospitalized patients 6. Regular meals

Exclusion Criteria

* 1\. Unwilling to participate or unable to cooperate.
* 2\. Myocardial infarction or cardiovascular and cerebrovascular events in the last 3 months;
* 3\. Glomerular filtration rate \< 45 ml/min / 1.73 m2;
* 4\. Other serious concomitant diseases;
* 5\. Liver function transaminase is 2 times higher than the upper limit of normal range;
* 6\. Use of oral hypoglycemic drugs other than metformin
* 7\. Asymptomatic hypoglycemia

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No